摘要
Yi-Qi-Huo-Xue Decoction(YQHX)is the recombination of Dang-Gui-Bu-Xue Decoction(DBD),which is one of the well-known traditional Chinese Medicine(TCM)prescription,and has long been shown to have significant protective effects against myocardial ischemic injury.In previous studies,we found that YQHX could regulate lipid and glucose metabolism,promote angiogenesis,attenuate inflammatory response,and ameliorate left ventricular function in myocardial ischemia rat models.However,the underlying mechanism of how YQHX involves in lipid metabolism remains unclear so far.In this study,the underlying mechanism of YQHX in lipid metabolism disorders was elucidated in a myocardial ischemia rat model and a hypoxia-induced H9 c2 cell injury model.YQHX(8.2 g·kg-1)and positive-control drug trimetazidine(10 mg·kg-1)were administered daily on the second day after left anterior descending(LAD)operation.At 7 days and 28 days after surgery,changes of cardiac morphology,structure,and function were evaluated by H&E staining and echocardiography,respectively.The plasma lipid levels and mitochondrial ATP content were also evaluated.Western blot and RT-PCR were used to determine the protein and mRNA expressions of AMPK,PGC-1α,CPT-1α,and PPARα.YQHX improved cardiac function and ameliorated lipid metabolism disorders.Furthermore,YQHX increased the expression of p-AMPK,PGC-1α,and CPT-1αwithout changing PPARαin ischemic rat myocardium.In vitro,YQHX activated the protein and mRNA expression of PGC-1α,CPT-1α,and PPARαin hypoxia-induced H9 c2 cells injury,whereas AMPK inhibitor Compound c blocked the effects of YQHX.Taken together,the results suggest that YQHX reduces lipid metabolism disorders in myocardial ischemia via the AMPK-dependent signaling pathway.
基金
the National Natural Science Foundation of China(No.81473552)
the China Postdoctoral Science Foundation(No.2019TQ0043)。